Cantor Fitzgerald Cuts Aptinyx (NASDAQ:APTX) Price Target to $5.00

Aptinyx (NASDAQ:APTXGet Rating) had its price objective trimmed by Cantor Fitzgerald from $11.00 to $5.00 in a research report report published on Friday morning, The Fly reports. The firm currently has an overweight rating on the stock.

A number of other equities research analysts have also recently weighed in on APTX. SVB Leerink decreased their price objective on Aptinyx from $12.00 to $10.00 and set an outperform rating for the company in a research note on Monday, December 20th. William Blair cut Aptinyx from an outperform rating to a market perform rating in a research note on Thursday. Finally, Zacks Investment Research cut Aptinyx from a buy rating to a hold rating in a research note on Friday, March 25th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus price target of $5.80.

Shares of APTX stock opened at $1.38 on Friday. The company has a current ratio of 20.18, a quick ratio of 20.18 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $93.45 million, a price-to-earnings ratio of -1.24 and a beta of 1.09. Aptinyx has a twelve month low of $1.14 and a twelve month high of $4.73. The stock has a fifty day simple moving average of $2.95 and a two-hundred day simple moving average of $2.67.

Aptinyx (NASDAQ:APTXGet Rating) last issued its quarterly earnings data on Wednesday, March 23rd. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. During the same period in the previous year, the firm earned ($0.20) EPS. Research analysts predict that Aptinyx will post -1.18 EPS for the current fiscal year.

In other Aptinyx news, Director Joan W. Miller bought 17,700 shares of Aptinyx stock in a transaction that occurred on Thursday, January 13th. The shares were bought at an average cost of $2.83 per share, with a total value of $50,091.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 7.94% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in shares of Aptinyx by 244.5% in the second quarter. Royal Bank of Canada now owns 9,288 shares of the company’s stock valued at $26,000 after purchasing an additional 6,592 shares during the period. Commonwealth Equity Services LLC acquired a new position in shares of Aptinyx in the fourth quarter valued at about $29,000. Blair William & Co. IL acquired a new position in shares of Aptinyx in the fourth quarter valued at about $51,000. Lindbrook Capital LLC acquired a new position in shares of Aptinyx in the fourth quarter valued at about $53,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Aptinyx in the fourth quarter valued at about $54,000. 50.34% of the stock is currently owned by institutional investors.

Aptinyx Company Profile (Get Rating)

Aptinyx Inc is a clinical stage biopharmaceutical company. It engages in the discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G.

Read More

The Fly logo

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.